Boston Scientific enters into $2 billion accelerated share repurchase agreement

Rhea-AI Summary

Boston Scientific (NYSE: BSX) entered a $2 billion accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank under its $5 billion authorization. The company will initially receive about 30.4 million shares, with final settlement by June 30, 2026, and expects a $0.02 boost to full-year 2026 adjusted EPS. After completion, $3 billion will remain available under the repurchase authorization.

AI-generated analysis. Not financial advice.

Positive

• $2 billion accelerated share repurchase initiated under existing $5 billion authorization
• Initial delivery of approximately 30.4 million shares based on $52.68 price
• $3 billion share repurchase capacity remains available after ASR completion
• ASR expected to add $0.02 to full-year 2026 adjusted EPS guidance

Negative

• Commits $2 billion of cash resources to share repurchases
• Final share count depends on VWAP and discount, adding settlement uncertainty

News Market Reaction – BSX

+6.15%

87 alerts

+6.15% News Effect

+2.7% Peak in 5 hr 18 min

+$4.85B Valuation Impact

$83.71B Market Cap

0.5x Rel. Volume

On the day this news was published, BSX gained 6.15%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.7% during that session. Our momentum scanner triggered 87 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $4.85B to the company's valuation, bringing the market cap to $83.71B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

ASR size: $2 billion Buyback authorization: $5 billion Initial delivery value: 80% of repurchase price +5 more

8 metrics

ASR size $2 billion Repurchase price under accelerated share repurchase agreement

Buyback authorization $5 billion Previously announced total share repurchase authorization

Initial delivery value 80% of repurchase price Initial common stock received under ASR terms

Initial shares estimate 30.4 million shares Based on May 15, 2026 closing price of $52.68

Reference share price $52.68 Closing price on May 15, 2026 used for initial ASR calculation

Remaining authorization $3 billion Buyback capacity remaining after this ASR

EPS impact 2026 $0.02 Expected net accretion to adjusted EPS full year 2026

ASR final settlement June 30, 2026 Expected completion date of accelerated share repurchase

Market Reality Check

Price: $49.13 Vol: Volume 14,753,642 is belo...

normal vol

$49.13 Last Close

Volume Volume 14,753,642 is below the 20-day average of 20,221,429, suggesting no pre-news accumulation signal. normal

Technical At $52.68, shares trade below the 200-day MA of $87.45 and sit near the 52-week low.

Peers on Argus

BSX was down 1.62% pre-news. Key peers like SYK, MDT, ABT and PHG also showed de...

BSX was down 1.62% pre-news. Key peers like SYK, MDT, ABT and PHG also showed declines, while EW was positive, and the momentum scanner flagged this as stock-specific rather than a broad sector rotation.

Historical Context

5 past events · Latest: May 06 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
May 06	PEN Q1 earnings	Positive	+1.0%	Penumbra Q1 2026 revenue growth and segment detail amid BSX acquisition.
May 04	Conference & Q2 call	Positive	+0.6%	Announcement of Bernstein conference appearance and Q2 2026 earnings call.
Apr 22	BSX Q1 earnings	Positive	+9.1%	Strong Q1 2026 net sales, EPS metrics, and multiple growth and approval wins.
Mar 30	Q1 call notice	Neutral	-9.0%	Scheduling and webcast details for April 22, 2026 Q1 results call.
Mar 30	FDA 510(k) clearance	Positive	-9.0%	FDA 510(k) clearance for Asurys Fluid Management System and limited US launch.

Pattern Detected

Recent BSX news skewed positive, with strong Q1 2026 earnings prompting a notable gain, while some conference and product-clearance headlines coincided with declines, indicating occasional divergence between fundamentals and short-term price moves.

Recent Company History

Over the past several months, Boston Scientific reported solid operational progress. On April 22, 2026, Q1 2026 net sales reached $5.203 billion with both GAAP and adjusted EPS disclosed, and the stock rose 9.09%. Prior and subsequent conference-call announcements in late March and early May outlined timing for Q1 and Q2 2026 results. A 510(k) clearance for the Asurys Fluid Management System was also announced on March 30, 2026. Against this backdrop of growth, product approvals and regular investor communication, the new accelerated share repurchase focuses on capital return.

Market Pulse Summary

The stock moved +6.2% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +6.2% in the session following this news. A strong positive reaction aligns with the clearly shareholder-friendly nature of a large buyback. The $2 billion accelerated share repurchase, within a broader $5 billion authorization, and expected $0.02 boost to 2026 adjusted EPS, signaled confidence in the business. However, with shares trading near the 52‑week low and below the 200-day MA, investors would have needed to weigh whether the capital return alone justified sustained strength without additional fundamental catalysts.

Key Terms

accelerated share repurchase, volume-weighted average price, adjusted earnings per share

3 terms

accelerated share repurchase financial

"entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank"

An accelerated share repurchase is a deal where a company hires a bank to buy back a large block of its own stock immediately on the open market, with the bank later settling the exact number of shares over time. For investors it matters because the immediate reduction in shares outstanding can raise per‑share earnings and often supports the stock price, but it also uses company cash or borrowing and can change liquidity and future growth funding.

volume-weighted average price financial

"determined based on the volume-weighted average price of the company's common stock"

Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.

adjusted earnings per share financial

"The expected net impact to adjusted earnings per share from the accelerated share repurchase"

Adjusted Earnings Per Share shows how much profit a company makes for each share of stock, but it removes unusual or one-time items like big expenses or gains. This helps investors see the company's true ongoing performance, making it easier to compare how well different companies are doing over time.

AI-generated analysis. Not financial advice.

MARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, National Association for $2 billion (the repurchase price) of its common stock, as part of its previously announced $5 billion share repurchase authorization. Under the terms of the ASR, Boston Scientific will pay the repurchase price and receive common stock with an aggregate value of 80% of the repurchase price based on the closing share price of the company's common stock as of May 15, 2026: this represents approximately 30.4 million shares based on the May 15, 2026, closing price of $52.68. The total number of shares that Boston Scientific will ultimately repurchase under the ASR will be determined based on the volume-weighted average price of the company's common stock during the term of the ASR, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR agreement. The final settlement of the ASR is expected to be completed by June 30, 2026. Following completion of the ASR, Boston Scientific will have $3 billion remaining available under the share repurchase authorization.

The expected net impact to adjusted earnings per share from the accelerated share repurchase in full year 2026 is $0.02, accretive to Boston Scientific's previously issued guidance on April 22, 2026.

About Boston Scientific 
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.

Cautionary Statement Regarding Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding the benefits of the ASR and the expected impact to adjusted earnings per share, the number of shares to be repurchased under the ASR and the timing and manner of the final settlement under the ASR agreement, business plans and strategy, and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the forward-looking statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things:  economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical events, conflicts and tensions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; market competition for our products; expected procedural volumes; new product introductions; demographic trends; the closing and integration of acquisitions; clinical trial results; intellectual property; litigation; financial market conditions; future business decisions made by us and our competitors; and the execution and effect of our business strategy, including our cost-savings and growth initiatives. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release.

CONTACTS: 
Chanel Hastings 
Media Relations
+1 (508) 382-0288
Chanel.Hastings@bsci.com 

Lauren Tengler
Investor Relations
+1 (508) 683-4479
BSXInvestorRelations@bsci.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-enters-into-2-billion-accelerated-share-repurchase-agreement-302774240.html

SOURCE Boston Scientific Corporation

FAQ

What did Boston Scientific (BSX) announce about its $2 billion share repurchase on May 18, 2026?

Boston Scientific announced a $2 billion accelerated share repurchase (ASR) with JPMorgan Chase Bank. According to Boston Scientific, the ASR is part of its previously authorized $5 billion buyback program and is expected to settle by June 30, 2026.

How many Boston Scientific (BSX) shares are initially delivered under the 2026 ASR agreement?

The ASR will initially deliver common stock worth 80% of the repurchase price. According to Boston Scientific, this equals approximately 30.4 million shares, based on the $52.68 closing price of its common stock on May 15, 2026.

How will the $2 billion ASR affect Boston Scientific (BSX) earnings per share in 2026?

The ASR is expected to increase 2026 adjusted EPS by $0.02. According to Boston Scientific, this impact is described as accretive to its previously issued full-year 2026 adjusted earnings per share guidance from April 22, 2026.

How is the final number of Boston Scientific (BSX) shares in the 2026 ASR determined?

The final share count will be based on the volume-weighted average price (VWAP) of BSX shares during the ASR term. According to Boston Scientific, this VWAP will be reduced by a discount and subject to adjustments under the ASR agreement.

What share repurchase capacity will Boston Scientific (BSX) have remaining after the $2 billion ASR?

After the ASR is completed, Boston Scientific will have $3 billion remaining under its share repurchase authorization. According to Boston Scientific, this residual capacity reflects the unused portion of its previously announced $5 billion buyback program.

When is the final settlement date for the Boston Scientific (BSX) $2 billion ASR?

Final settlement of the ASR is expected by June 30, 2026. According to Boston Scientific, the ultimate number of shares repurchased will be calculated at that time using the volume-weighted average price of its common stock over the ASR term.